术前NLR与PLR对结直肠癌预后的意义

目的研究术前外周血中中性粒细胞、淋巴细胞、血小板的相互比值与结直肠癌预后之间的相关性。方法收集2011年1月至2015年12月在延边大学附属医院行结直肠癌根治性手术的417例患者的临床、病理学资料,分析中性粒细胞、淋巴细胞、血小板与结直肠癌预后指标之间的相关性。结果中性粒细胞和淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)与TNM分期、T分期、N分期之间差异有统计学意义(P0.05),与M分期之间差异无统计学意义(P0.05),NLR≤1.57组和NLR1.57组的5年生存率分别为77.14%、20.78%,两组间差异有统计学意义(P0.05);血小板和淋巴细胞比值(platelet to lymphocyteratio ratio,PLR)与TNM分期、T分期、N分期、M分期之间差异均无统计学意义(P0.05)。结论术前NLR可有效评估结直肠癌预后,为结直肠癌患者及临床治疗提供预后指标。     

NLR、PLR、LMR与126例食管小细胞癌临床病理特征及预后的关系分析

摘 要：［目的］ 探讨食管小细胞癌（small cell carcinoma of the esophagus,SCCE）术后中性粒细胞/淋巴细胞比值（neutrophil/lymphocyte ratio,NLR）、血小板/淋巴细胞比值（platelet/lymphocyte ratio,PLR）、淋巴细胞/单核细胞比值（lymphocyte/monocyte ratio,LMR）与临床病理特征及预后的相关性。［方法］ 回顾性分析河北省肿瘤医院收治的126例SCCE手术患者,分析NLR、PLR、LMR与SCCE临床病理特征及预后的关系。［结果］ 术后SCCE患者中NLR与肿瘤大小、局部浸润深度、淋巴结转移和TNM分期相关;PLR与局部浸润深度、淋巴结转移、远处转移和TNM分期相关;LMR与局部浸润深度、远处转移和TNM分期相关。单因素分析显示：肿瘤大小、局部浸润深度、淋巴结转移、远处转移、TNM分期、NLR、PLR和LMR水平与预后相关。多因素Cox回归分析显示：NLR、PLR、LMR、远处转移和TNM分期是SCCE患者的独立预后因素,高NLR组、高PLR组和低LMR组患者预后较差。［结论］ NLR、PLR和LMR三者均可较好地预测SCCE患者的预后,是一种简捷有效的术后评估及预后分析指标。     

术前NLR、PLR在非小细胞肺癌患者预后中的价值

目的：评估术前中性粒细胞/淋巴细胞比值（neutrophil to lymphocyte ratio, NLR）、血小板/淋巴细胞比值（platelet to lymphocyte ratio, PLR）在非小细胞肺癌（non-small cell lung cancer, NSCLC）患者预后中的价值。方法：回顾性分析2012年1月至2014年4月四川省肿瘤医院行根治性手术治疗的280例NSCLC患者的临床病理资料，根据受试者工作特征曲线（receiver operating characteristic curve, ROC）确定NLR、PLR的临界值，分析NLR、PLR与患者预后的相关性。结果：选取NLR=3.25和PLR=122作为临界值。单因素分析显示TNM分期、T分期、N分期与无病生存期（disease-free survival, DFS）相关，P值分别为0.001、0.007、＜0.001；年龄、TNM分期、T分期、N分期、PLR与总生存期（overall survival, OS）相关，P值分别为0.006、＜0.001、0.035、＜0.001、＜0.001。多因素分析显示TNM分期（HR：1.627 ,95% CI：1.030-2.568，P=0.037）是影响DFS的独立危险因素。年龄（HR：1.785，95% CI：1.216-2.622，P = 0.003）、TNM分期（HR：2.094，95% CI：1.231-3.560，P = 0.006）、PLR（HR：1.833，95% CI：1.257-2.674，P = 0.002）是影响OS的独立危险因素。结论：PLR可作为评估经根治性手术治疗NSCLC患者预后的参考指标。     

淋巴细胞相关炎性反应指标与乳腺癌预后的相关性

目的 探讨治疗前中性粒细胞淋巴细胞比（NLR）、淋巴细胞单核细胞比（LMR）、血小板淋巴细胞比（PLR）与乳腺癌患者临床病理特征及预后的关系。 方法 回顾性分析189例乳腺癌患者的临床资料，应用ROC曲线获得NLR、LMR、PLR的临界值。根据临界值将患者分为高低两组，分析NLR、LMR、PLR与临床病理特征及预后的相关性。结果 NLR、LMR、PLR最佳临界值分别为2.4、5.4、113。高低NLR组患者的新辅助化疗和手术治疗差异有统计学意义（均P<0.05），高低LMR组和PLR组患者在各临床病理特征方面差异无统计学意义（均P>0.05）。单因素分析结果显示，TNM临床分期、PR表达、NLR、LMR、PLR、手术以及内分泌治疗均与OS有关（均P<0.05）；TNM临床分期、HER2表达、NLR、手术以及内分泌治疗均与PFS有关（均P<0.05）。多因素分析结果显示，TNM临床分期（P=0.003）和NLR（P=0.033）是OS的独立危险因素；TNM临床分期（P=0.002）和手术治疗（P=0.040）是PFS的独立影响因素。结论 治疗前NLR、LMR、PLR与乳腺癌的预后存在显著相关性，但仅NLR是独立危险因素，LMR、PLR尚不能作为独立预测因子。     

NLR、PLR在非小细胞肺癌患者治疗及预后中的作用研究进展

摘 要：早在19世纪已有学者发现肿瘤与炎症之间存在某种关系，近几年肿瘤与炎症关系的探讨一直是学界热点问题，其中中性粒细胞与淋巴细胞比值（neutrophil to lymphocyte ratio，NLR）和血小板与淋巴细胞比值（platelet to lymphocyte ratio，PLR）是研究的焦点。有关NLR、PLR与非小细胞肺癌（non-small cell lung cancer，NSCLC）关系的研究显示NLR和PLR与NSCLC癌患者治疗后的生存状态有关，较高的NLR和PLR常提示患者不良的预后状态。全文就NLR和PLR与NSCLC诊断、分期及治疗的关系作一分析。     

术前NLR、PLR与三阴性乳腺癌患者预后的相关性分析

目的:探讨术前外周血中性粒细胞与淋巴细胞计数比值(NLR)联合血小板与淋巴细胞计数比值(PLR)对三阴性乳腺癌(TNBC)患者预后的评估价值。方法:收集155例TNBC患者，根据NLR水平分为低NLR组和高NLR组，根据PLR水平分为低PLR组和高PLR组，分别分析NLR和PLR与TNBC患者临床特征和预后的关系，采用χ2检验进行影响患者预后的单因素分析，Kaplan-Meier法绘制生存曲线，Cox回归模型分析影响患者预后的独立危险因素。结果:术前外周血NLR与TNBC患者的淋巴结转移、病理分期及复发转移有关(P＜0.05)，与年龄、肿瘤大小、组织学分级及月经均无关(P＞0.05)。PLR与TNBC患者的临床特征无关(P＞0.05)。单因素分析结果显示:淋巴结转移、病理分期、NLR、复发转移与患者的3年无病进展期相关。Cox回归模型多因素分析结果显示，病理分期、淋巴结转移、NLR是影响TNBC患者预后的独立风险因素。结论:NLR与 TNBC患者的病理分期、淋巴结转移及复发转移密切相关，高NLR可作为判断患者预后的独立危险因素；PLR与TNBC患者的临床特征及预后无明显相关性。     

胃癌患者术前NLR PLR RDW值与病理参数的关系

  目的  研究外周血中性粒细胞与淋巴细胞比值（neutrophil-to-lymphocyte ratio,NLR）、血小板与淋巴细胞比值（platelet-tolymphocyte ratio,PLR）、红细胞分布宽度（red blood cell distribution width,RDW）与胃癌患者术后临床病理参数之间的关系。  方法  回顾性分析福建省肿瘤医院2012年2月至2014年12月初诊入院手术的434例胃癌患者术前全血细胞计数及术后病理资料,同时选取年龄及性别匹配的342例慢性萎缩性胃炎患者及309例健康对照者进行对比分析。  结果  胃癌组NLR、PLR和RDW的中位数值显著高于胃炎及正常对照组（P < 0.000 1）。Kruskal-Wallis相关分析显示患者NLR、PLR及RDW值随着病理分期的进展逐步升高（NLR、PLR:P < 0.000 1;RDW:P < 0.05）,但与肿瘤分化程度和肿瘤生长部位无显著相关。多因素回归分析结果表明NLR和PLR是肿瘤病理分期和T分期的独立相关因素（P < 0.000 1）。ROC曲线分析结果显示NLR和PLR对术前预判胃癌T分期有一定诊断疗效。  结论  胃癌患者术前NLR及PLR值与胃癌TNM分期密切相关,可作为术前分期预判的非特异性标志物。      

术前高血小板和淋巴细胞比值是早期恶性黑色素瘤患者的不良预后因素

[摘要] 目的：探讨术前血液中血小板、单核细胞、中性粒细胞与淋巴细胞的比值指标与早期恶性黑色素瘤（malignant melanoma,MM）患者临床病理特征及预后的相关性。方法：收集2007 年1 月到2012 年5 月在天津医科大学肿瘤医院初治并接受根治术的120 例Ⅰ~Ⅲ期皮肤MM患者的临床资料,分析术前血液中血小板和淋巴细胞比值（platelet-to-lymphocyte ratio,PLR）、淋巴细胞和单核细胞比值（lymphocyte-to-monocyte ratio,LMR）、中性粒细胞和淋巴细胞比值（neutrophil-to-lymphocyte,NLR）,以及血红蛋白、中性粒细胞、淋巴细胞、单核细胞、嗜酸性粒细胞、嗜碱性粒细胞、血小板、乳酸脱氢酶、年龄、肿瘤分期和溃疡等与MM患者临床病理特征及预后的关系。结果：原发病灶有溃疡患者的NLR及嗜碱性粒细胞较高（均P<0.05）。单因素分析结果显示PLR、NLR、LMR、中性粒细胞数、淋巴细胞数、单核细胞数、乳酸脱氢酶水平、年龄、肿瘤分期和溃疡是MM患者5 年生存率的影响因素（P<0.05）。多因素分析结果发现,PLR（HR=4.206,95%CI:1.654~10.696,P<0.01）、肿瘤分期（HR=7.670,95%CI: 3.977~14.795,P<0.01）和溃疡（HR=1.931,95%CI:1.029~3.623,P<0.05）是影响MM患者预后的独立危险因素。结论：术前高PLR 可以作为早期MM患者不良预后的判断因素。     

外周血血小板/淋巴细胞比值与胆道系统肿瘤预后的相关性

摘 要：［目的］ 探讨外周血血小板/淋巴细胞比值（platelet to lymphocyte ratio,PLR）与胆道系统恶性肿瘤临床病理特征的相关性及其对预后的影响。［方法］ 系统回顾126例胆道系统肿瘤患者的临床病理资料,PLR分组根据格拉斯哥预后评分(The Glasgow Prognostic Score,GPS )中对PLR定义的界值,将PLR分为低PLR组（PLR<150）和高PLR组（PLR≥150）。分析PLR水平与胆道系统肿瘤患者临床病理因素的相关性;通过单因素、多因素分析探讨PLR与胆道系统肿瘤预后的相关性。［结果］高PLR组胆道系统肿瘤患者的总生存期（overall survival,OS）与无进展生存期（progression-free survival,PFS）均低于低PLR组,但差异均无统计学意义（P>0.05）;单因素分析结果显示纤维蛋白原（Fibrinogen,FG）与胆道系统肿瘤患者的OS和PFS的均有相关性（P<0.05）;年龄、PS评分及中性粒细胞与淋巴细胞比值( neutrophil to lymphocyte ratio,NLR)与PFS有相关性（P<0.05）;肿瘤部位、TNM分期与OS有相关性（P<0.05）。多因素分析结果表明年龄、FG是胆道系统肿瘤预后的独立危险因素。分层分析结果显示,不同年龄分组中,PLR与OS和PFS均无相关性（P>0.05）。［结论］目前样本分析结果表明PLR不能作为胆道系统肿瘤预后的一个指标,但仍需继续扩大样本量进一步证实。     

血小板与淋巴细胞比值预测三阴性乳腺癌临床预后及与免疫球蛋白表达的关系

目的:探讨血小板与淋巴细胞比值（platelet to lymphocyte ratio，PLR）对三阴性乳腺癌的临床预后影响及与免疫球蛋白表达的关系。方法:回顾性分析2006年1月至2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan-Meier和log-rank方法。结果:PLR是三阴性乳腺癌的独立预后因素，最佳临界值为155.00。PLR＜155.00组，术后中位DFS为35.51月，中位OS为55.24月；PLR≥155.00组，术后中位DFS为25.07月，中位OS为35.17月。两组术后DFS和OS比较，差异具有统计学意义（P＜0.05）。结论:PLR是三阴性乳腺癌的独立预后因素，具有重复性强、非侵袭性、方便实用等特性，可用于预测三阴性乳腺癌临床预后。     

Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios are Not Different among Breast Cancer Subtypes

Background: Breast cancer is a heterogeneous complex of diseases comprising different subtypes that have different treatment responses and clinical outcomes. Systemic inflammation is known to be associated with poor prognosis in many types of cancer. The neutrophil / lymphocyte ratio (NLR) and platelet / lymphocyte ratio (PLR) are factors used as indicators of inflammation. In this study, we evaluated NLR and PLR ratios in breast cancer subtypes. Methods: A total of 255 breast cancer patients were evaluated retrospectively. Patients were classified into three subtypes: estrogen receptor (ER)- or progesterone receptor (PR)-positive tumors were classified as luminal tumors; human epidermal growth factor receptor-2 (HER2)-overexpressed and ER-negative tumors were classified as HER2-positive tumors; and ER, PR, and HER2-negative tumors were classified as triple-negative tumors. The NLR and PLR were calculated. Results: The median NLR and PLR were 3 (0.37–37,1) and 137 (37.1–421.3), respectively. 66.7% of the patients were luminal type, 19.2% were HER2 positive, and 14.1% were triple negative. NLR was not associated with grade (p: 0.412), lymphovascular invasion (p: 0.326), tumor size (p: 0.232) and metastatic lymph node involvement (p: 0.406). PLR was higher in the patients with lymph node metastasis than in those without lymph node metastasis (p: 0.03). The NLR was 2 in the luminal group, 1.8 in the HER2-positive group, and 1.9 in the triple-negative group, but the differences were not significant(p: 0.051). PLR was 141 in the luminal group, 136 in the HER2-positive group, and 130 in the triple-negative group, but the differences were not significant. Conclusion: We could not find any significant differences for NLR and PLR according to breast cancer subtypes.     

放疗前中性粒细胞/淋巴细胞血小板/淋巴细胞预后营养指数及CA19-9与胰腺腺癌放疗后预后关系的分析

  目的  探讨胰腺癌患者放疗前外周血中性粒细胞与淋巴细胞的比值（neutrophil to lymphocyte ratio,NLR）、血小板与淋巴细胞的比值（platelet to lymphocyte ratio,PLR）、预后营养指数（prognostic nutritional index,PNI）及糖类抗原19-9（carbohydrate antigen 19-9,CA19-9）与总生存时间（overall survival,OS）关系。  方法  回顾性分析2008年3月~2013年3月空军总医院61例经病理确诊为胰腺腺癌的患者临床资料,并通过电子病历查询患者治疗前检验结果,通过电子病历记录或电话随访获得患者OS。采用Ka? plan-Meier方法构建生存曲线,组间差异比较用Log-rank检验,单因素及多因素的分析运用Cox比例风险模型进行。  结果  利用log-rank检验及单因素回归分析,提示NLR、PLR、CA19-9增高、PNI降低、TNM分期晚,患者生存期短,差异具有统计学意义。多因素回归分析显示,NLR（P=0.029,OR 2.344,95%CI:1.090~5.041）;PNI（P=0.026,OR 0.477,95%CI:0.248~0.917）是胰腺癌患者OS的独立影响因素。  结论  NLR、PLR、PNI等是评价胰腺癌患者预后较为简单、有效的可靠指标之一.      

Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy

Purpose

Proinflammatory markers, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), are associated with many aspects of different malignancies. The aim of this study was to assess the associations of NLR and PLR with estrogen receptor (ER) and progesterone receptor (PR) expression in locally advanced breast cancer patients and their changes after neoadjuvant chemotherapy (NAC). Whether these parameters were predictive for the response to NAC in breast cancer patients was also evaluated.

Methods

132 Female primary locally advanced breast cancer patients treated with either ET (epirubicin–docetaxel), TEC (docetaxel–epirubicin–cyclophosphamide), or CEF (cyclophosphamide–epirubicin–fluorouracil) as NAC were retrospectively studied. NLR and PLR were calculated from peripheral blood cell count and their optimal cutoff levels were determined by receiver operating characteristic curves.

Results

The proportion of ER-positive breast cancers before NAC was higher both in NLR^low (<2.05) group and PLR^low group (<159.01). Changes in ER or PR expression level or status were observed in some patients. The alterations of NLR and PLR after NAC correlated with chemotherapy regimens, and elevated PLR was found. The patients with low pretreatment NLR (<1.67) or PLR (<151.27) had better responses to NAC than those with high NLR (≥1.67, 67.3 vs. 47.1%, P < 0.05) or PLR (≥151.27, 64.0 vs. 45.1%, P < 0.05).

Conclusions

The patients with low pretreatment NLR (<2.05) or PLR (<159.01) had higher ER expression. Changes in ER and PR expression status or level occured following NAC. Elevated PLR was found aft-NAC. Pretreatment NLR and PLR may be important predictive indicators for NAC response in breast cancer patients.

     

中性粒细胞/淋巴细胞比值血小板/淋巴细胞比值与TACE治疗肝癌患者预后的相关性

  目的  本研究探讨中性粒细胞与淋巴细胞比值（neutrophil to lymphocyte ratio,NLR）和血小板与淋巴细胞比值（platelet to lymphocyte ratio,PLR）与接受肝动脉栓塞化疗（transarterial chemoembolization,TACE）肝癌（hepatocellular carcinoma,HCC）患者术后生存期的相关性。  方法  回顾性分析2007年1月至2015年6月中山大学肿瘤防治中心肝胆胰科确诊为肝癌并行TACE治疗的216例患者。研究患者依照NLR和PLR的界值分成两组。分析并比较NLR和PLR在不同随访时间点的受试者工作曲线（ROC）下面积。单因素和多因素分析用于评价NLR和PLR与TACE术后肝癌患者预后的相关性。  结果  本研究中位随访时间为431.1 d。全体研究对象1、2、3年生存率分别为61.3%、44.2%和40.5%。中位生存时间为410.5 d。术前NLR＜1.77组和术前NLR≥1.77组1、2、3年生存率分别为81.6%、63.0%、45.7%和43.1%、27.0%、19.3%,差异具有统计学意义（P < 0.001）。术前PLR < 94.62组和术前PLR≥94.62组1、2、3年生存率分别为62.7%、47.0%、37.0%和46.8%、29.0%、18.5%,差异具有统计学意义（P=0.002）。多因素分析显示NLR≥1.77与TACE术后肝癌患者较差预后相关,是肝癌患者TACE治疗后的危险因素。  结论  TACE介入术前HCC患者的NLR水平,作为系统炎症的一个反应指标,是影响其预后的危险因素。      

Elevated Serum Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios Could be Useful in Lung Cancer Diagnosis

Background: Lung cancer (LC) is still the primary cause of cancer deaths worldwide, and late diagnosis is amajor obstacle to improving lung cancer outcomes. Recently, elevated preoperative or pretreatment neutrophilto lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) detected inperipheral blood were identified as independent prognostic factors associated with poor survival with variouscancers, including colon cancer, esophageal cancer, gastric cancer and breast cancer. Objective: The aim ofthis study was to examine whether MPV, NLR and PLR could be useful inflammatory markers to differentiatelung cancer patients from healthy controls. An investigation was also made of the relationship between thesemarkers and other prognostic factors and histopathological subgroups. Materials and Methods: Retrospectivelyeighty-one lung cancer patients and 81 age-sexes matched healthy subjects included into the study. Patientswith hypertension, hematological and renal disease, heart failure, chronic infection, hepatic disorder and othercancer were excluded from the study. The preoperative or pretreatment blood count data was obtained fromthe recorded computerized database. Results: NLR and PLR values were significantly higher in the LC patientscompared to the healthy subjects.( NLR: 4.42 vs 2.45 p=0.001, PLR: 245.1 vs 148.2 p=0.002) MPV values weresimilar in both groups (7.7 vs 7.8). No statistically significant relationship was determined between these markers(MPV, NLR and PLR) and histopathological subgroups and TNM stages. Conclusions: NLR and PLR can beuseful biomarkers in LC patients before treatment. Larger prospective studies are required to confirm thesefindings.     

非小细胞肺癌免疫治疗前后N LR和PLR变化及对免疫治疗疗效的预测价值

目的:探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)和血小板/淋巴细胞比值(platelet to lymphocyte ratio,PLR)及其动态变化对非小细胞肺癌(non-small cell lung cancer,NSCLC)免疫治疗疗效和预后的影响.方法...     

结直肠癌初治患者外周血中性粒细胞与淋巴细胞比值与临床病理特征的关系及其预后价值分析

目的 探讨结直肠癌初治患者外周血中性粒细胞与淋巴细胞比值(NLR)与临床病理特征及预后的关系.方法 选取结直肠癌患者387例,观察患者术前NLR与临床病理特征及预后的关系.结果 不同性别、年龄、肿瘤部位、肿瘤大小、淋巴结转移、远处转移、浸润程度和分化程度结直肠癌患者的NLR比较,差异无统计学意义(P﹥0.05);血小板≥350×109/L结直肠癌患者的术前NLR高于血小板﹤350×109/L的患者(P﹤0.05);TNM分期为Ⅲ、Ⅱ期结直肠癌患者的术前NLR均高于Ⅰ期患者(P﹤0.05);高NLR组患者的中位生存时间为35.41个月(95%CI:25.93~46.03),低于低NLR组的42.81个月(95%CI:33.39~58.10)(P﹤0.05);低NLR组TNM分期为Ⅰ、Ⅱ、Ⅲ期患者的中位生存期分别为42.65个月、42.01个月和41.04个月,差异无统计学意义(χ2=2.382,P﹥0.05);高NLR组TNM分期为Ⅰ、Ⅱ、Ⅲ期患者的中位生存期分别为37.03个月、36.52个月和35.02个月,差异无统计学意义(χ2=3.082,P﹥0.05).结论 结直肠癌初治患者术前NLR与患者的临床病理特征及预后有一定关系,值得进一步研究.     

Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratioin predicting survival for patients with stage Ⅰ-Ⅱgastric cancerCSCD

Background:The preoperative neutrophil-to-lymphocyte ratio(NLR) and the platelet-to-lymphocyte ratio(PLR) are associated with poor prognosis of gastric cancer.We aimed to determine whether the combination of NLR and PLR(NLR-PLR) could better predict survival of patients after curative resection for stage Ⅰ-Ⅱ gastric cancer.Methods:We collected data from the medical records of patients with stage Ⅰ-Ⅱ gastric cancer undergoing curative resection between December 2000 and November 2012 at the Sun Yat-sen Cancer Center.The preoperative NLRPLR was calculated as follows:patients with both elevated NLR(≥2.1) and PLR(≥ 120) were given a score of 2,and patients with only one or neither were given a score of 1 or 0,respectively.Results:Kaplan-Meier analysis and log-rank tests revealed significant differences in overall survival(OS) among patients with NLR-PLR scores of 0,1 and 2(P < 0.001).Multivariate analysis showed that OS was independently associated with the NLR-PLR score[hazard ratio(HR) = 1.51,95%confidence interval(CI) 1.02-2.24,P = 0.039]and TNM stage(HR = 1.36,95%CI 1.01-1.83,P= 0.041).However,other systemic inflammation-based prognostic scores,including the modified Glasgow prognostic score,the prognostic nutritional index,and the combination of platelet count and NLR,were not.In TNM stage-stratified analysis,the prognostic significance of NLR-PLR was maintained in patients with stage Ⅰ(P < 0.001) and stage Ⅱ cancers(P= 0.022).In addition,the area under the receiver operating characteristic curve for the NLR-PLR score was higher than those of other systemic inflammation-based prognostic scores(P = 0.001).Conclusion:The preoperative NLR-PLR score is a useful predictor of postoperative survival in the patients with stage l-ll gastric cancer and may help identify high-risk patients for rational therapy and timely follow-up.